Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Blood (2024) 144 (Supplement 1): 959.

https://doi.org/10.1182/blood-2024-198745

Published: 2024

Journal Articles

First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors

Blood (2023) 142 (Supplement 1): 5957.

https://doi.org/10.1182/blood-2023-187642

Published: 2023

Journal Articles

Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel

Blood (2018) 132 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2018-99-115460

Published: 2018

Journal Articles

Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment

Greg D Whitehill, BS, Alicia Chivers, MS, Bryan Danielson, PhD, Julien SR Tessier, MS, Gabriela Hernandez Duran, Gabrielle L Bender, BS, Douglas W. Sborov, MD MSc, Craig C Hofmeister, MDMPH, James Bradner, MD, Teru Hideshima, MD PhD, Kenneth C Anderson, MD, Gullu Gorgun, PhD

Blood (2017) 130 (Supplement 1): 4422.

https://doi.org/10.1182/blood.V130.Suppl_1.4422.4422

Published: 2017

Journal Articles

The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival

Hiroto Ohguchi, MD PhD, Teru Hideshima, MDPhD, Manoj Bhasin, PhD, Gullu Gorgun, PhD, Loredana Santo, MD, Michele Cea, MD, Naoya Mimura, MD PhD, Rikio Suzuki, MDPhD, Yu-Tzu Tai, PhD, Ruben D. Carrasco, MD PhD, Noopur S. Raje, MD, Paul G. Richardson, MD, Hideo Harigae, MD PhD, Takaomi Sanda, MD PhD, Kenneth C. Anderson, MD

Blood (2015) 126 (23): 3633.

https://doi.org/10.1182/blood.V126.23.3633.3633

Published: 2015

Journal Articles

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blood (2012) 119 (24): 5772–5781.

https://doi.org/10.1182/blood-2011-07-366633

Published: 2012

Includes: Supplemental data

Journal Articles

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Blood (2011) 118 (21): 133.

https://doi.org/10.1182/blood.V118.21.133.133

Published: 2011

Journal Articles

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

Gullu Gorgun, PhD, Teru Hideshima, MD, PhD, Noopur S. Raje, MD, Naoya Mimura, MD, PhD, James E. Bradner, MD, Diana Cirstea, MD, Loredana Santo, MD, Yu-Tzu Tai, PhD, Michael Sellitto, Yiguo Hu, PhD, Claire Fabre, MD, PhD, Hiroto Ohguchi, MD, PhD, Jiro Minami, MD, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 128.

https://doi.org/10.1182/blood.V118.21.128.128

Published: 2011

Journal Articles

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

Claire Fabre, MD, PhD, Naoya Mimura, MD, PhD, Kathryn Bobb, MS, Gullu Gorgun, PhD, Diana D. Cirstea, MD, Yiguo Hu, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Jie Zhang, PhD, Jeffrey Meshulam, BS, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 2902.

https://doi.org/10.1182/blood.V118.21.2902.2902

Published: 2011

Journal Articles

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Diana Cirstea, MD, Teru Hideshima, MD, PhD, Loredana Santo, MD, Homare Eda, MD, PhD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Anuj K. Mahindra, MD, Gullu Gorgun, PhD, Yiguo Hu, MD, PhD, Naoya Mimura, MD, PhD, Claire Fabre, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Kenneth C. Anderson, MD, Sylvie M Guichard, PharmD, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2916.

https://doi.org/10.1182/blood.V118.21.2916.2916

Published: 2011

Journal Articles

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Niels W.C.J. van de Donk, MD, PhD, Henk M. Lokhorst, MD, Maarten Emmelot, Tineke Aarts-Riemens, Douglas W. McMillin, PhD, Gullu Gorgun, PhD, Steffen Klippel, PhD, Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Jake E Delmore, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1838.

https://doi.org/10.1182/blood.V118.21.1838.1838

Published: 2011

Journal Articles

Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells

Diana Cirstea, Teru Hideshima, Loredana Santo, Samantha Pozzi, Sonia Vallet, Kishan Patel, Gullu Gorgun, Yiguo Hu, Sylvie M Guichard, Anuj Mahindra, Kenneth C. Anderson, Noopur Raje

Blood (2010) 116 (21): 791.

https://doi.org/10.1182/blood.V116.21.791.791

Published: 2010

Journal Articles

Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma

Naoya Mimura, Teru Hideshima, Gullu Gorgun, Diana Cirstea, Loredana Santo, Yiguo Hu, Claire Fabre, Martina Blumenthal, Victor Tam, Nathalie L. Kertesz, Qingping Zeng, John B. Patterson, Nikhil C. Munshi, Paul Richardson, Kenneth C. Anderson

Blood (2010) 116 (21): 4074.

https://doi.org/10.1182/blood.V116.21.4074.4074

Published: 2010

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma

Gullu Gorgun, PhD, Teru Hideshima, MD, PhD, Naoya Mimura, MD, PhD, Diana Cirstea, M.D., Loredana Santo, MD, Yiguo Hu, MD, PhD, Claire Fabre, MD, Noopur Raje, MD, Nikhil C. Munshi, MD, Paul G Richardson, MD, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 2996.

https://doi.org/10.1182/blood.V116.21.2996.2996

Published: 2010

Journal Articles

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Güllü Görgün, Elisabetta Calabrese, Ender Soydan, Teru Hideshima, Giulia Perrone, Madhavi Bandi, Diana Cirstea, Loredana Santo, Yiguo Hu, Yu-Tzu Tai, Sabikun Nahar, Naoya Mimura, Claire Fabre, Noopur Raje, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson

Blood (2010) 116 (17): 3227–3237.

https://doi.org/10.1182/blood-2010-04-279893

Published: 2010

Includes: Supplemental data

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

Journal Articles

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Blood (2010) 115 (25): 5202–5213.

https://doi.org/10.1182/blood-2009-12-259523

Published: 2010

Includes: Supplemental data

Journal Articles

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Teru Hideshima, Constantine Mitsiades, Hiroshi Ikeda, Dharminder Chauhan, Noopur Raje, Gullu Gorgun, Hiromasa Hideshima, Nikhil C. Munshi, Paul G. Richardson, Daniel R. Carrasco, Kenneth C. Anderson

Blood (2010) 115 (18): 3772–3775.

https://doi.org/10.1182/blood-2010-02-270082

Published: 2010

Includes: Supplemental data

Journal Articles

Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.

Gullu Gorgun, PhD, Elisabetta Calabrese, MD, Teru Hideshima, MD, PhD, Giulia Perrone, MD, Giada Bianchi, MD, Hiroshi Ikeda, MD, PhD, Mala Mani, PhD, Yiguo Hu, MD, PhD, Diana Cristea, MD, Loredana Santo, MD, Yu-Tzu Tai, PhD, Nikhil Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 950.

https://doi.org/10.1182/blood.V114.22.950.950

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors

Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel

Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment

The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells

Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

PI3K/p110δ is a novel therapeutic target in multiple myeloma

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only